Abstract
We report on a 61-year-old postmenopausal female with schizophrenia included in a raloxifene vs. placebo clinical trial and monitored during a 12-month period including a 3-month withdrawal period (6–9 months) without treatment. The patient was treated with raloxifene 60 mg/day adjuvant to antipsychotic medication for 6 months, medication was then withdrawn for 3 months and was reintroduced due to a worsening of symptoms. We assessed the patient with PANSS and other neuropsychological tests. The patient improved in psychopathology and cognitive level in some aspects related to executive functions. During 3 months without the drug, the patient’s condition deteriorated. When the drug was reintroduced, improvements were again observed. Raloxifene may be useful as an adjuvant treatment for psychopathological symptoms and some cognitive aspects in women with chronic schizophrenia.
References
Benedet MJ, Alexandre MA (1998) Test de aprendizaje verbal España-Complutense (TAVEC). TEA, Madrid
Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M, Serrano-Blanco A, Teba F, Usall J (2014) Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 24:223–231
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
Kianimehr G, Fatehi F, Hashempoor S, Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L, Akhondzadeh S (2014) Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo-controlled trial. Daru 22:55
Ko SS, Jordan VC (2011) Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother 12:657–674
Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A, Berk M, Dodd S, Fitzgerald PB, Davis SR (2010) Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35:1142–1147
Landry M, Di Paolo T (2003) Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor. Brain Res Mol Brain Res 112:82–89
Landry M, Lévesque D, Di Paolo T (2002) Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 76:214–222
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and across-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334:1–100
Reitan R, Wolfson D (1995) Category test and trail making test as measures of frontal lobe functions. Clin Neuropsychol 9:50–56
Seisdedos N, Corral S, Cordero A, de la Cruz MV, Hernández MV, Pereña J (1999) WAIS III. Manual Técnico. TEA, Madrid
Strauss E, Sherman EMS, Spreen O (2006) A compendium of neuropsychological tests: administration, norms, and commen- tary, 3rd edn. Oxford University Press, New York
Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:643–662
Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, Serrano-Blanco A, Teba F, Ochoa S (2011) Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 72:1552–1557
Wong J, Seeman MV, Shapiro H (2003) Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. Am J Geriatr Psychiatry 11:697–698
Zec RF, Trivedi MA (2002) The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev 12:65–109
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huerta-Ramos, E., Ochoa, S., Roca, M. et al. The effect of raloxifene on symptoms and cognitive functioning in a postmenopausal schizophrenia patient: a case report. Arch Womens Ment Health 18, 259–261 (2015). https://doi.org/10.1007/s00737-015-0500-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00737-015-0500-9